Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 129.67
IDRA's Cash to Debt is ranked higher than
53% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. IDRA: 129.67 )
Ranked among companies with meaningful Cash to Debt only.
IDRA' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 129.67

Equity to Asset 0.94
IDRA's Equity to Asset is ranked higher than
92% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. IDRA: 0.94 )
Ranked among companies with meaningful Equity to Asset only.
IDRA' s 10-Year Equity to Asset Range
Min: -1.57   Max: 0.94
Current: 0.94

-1.57
0.94
F-Score: 3
Z-Score: 25.96
M-Score: 1.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -40675.00
IDRA's Operating margin (%) is ranked lower than
97% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -73.33 vs. IDRA: -40675.00 )
Ranked among companies with meaningful Operating margin (%) only.
IDRA' s 10-Year Operating margin (%) Range
Min: -53084.93   Max: 941.09
Current: -40675

-53084.93
941.09
Net-margin (%) -40540.38
IDRA's Net-margin (%) is ranked lower than
96% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. IDRA: -40540.38 )
Ranked among companies with meaningful Net-margin (%) only.
IDRA' s 10-Year Net-margin (%) Range
Min: -52934.25   Max: 57.33
Current: -40540.38

-52934.25
57.33
ROE (%) -62.62
IDRA's ROE (%) is ranked lower than
71% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. IDRA: -62.62 )
Ranked among companies with meaningful ROE (%) only.
IDRA' s 10-Year ROE (%) Range
Min: -302.28   Max: 194.96
Current: -62.62

-302.28
194.96
ROA (%) -56.80
IDRA's ROA (%) is ranked lower than
75% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: -23.47 vs. IDRA: -56.80 )
Ranked among companies with meaningful ROA (%) only.
IDRA' s 10-Year ROA (%) Range
Min: -181.34   Max: 63.38
Current: -56.8

-181.34
63.38
ROC (Joel Greenblatt) (%) -4810.33
IDRA's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. IDRA: -4810.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IDRA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11798.05   Max: 9024.79
Current: -4810.33

-11798.05
9024.79
EBITDA Growth (3Y)(%) -17.60
IDRA's EBITDA Growth (3Y)(%) is ranked lower than
66% of the 426 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. IDRA: -17.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IDRA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -69.8   Max: 4.8
Current: -17.6

-69.8
4.8
EPS Growth (3Y)(%) -23.00
IDRA's EPS Growth (3Y)(%) is ranked lower than
70% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. IDRA: -23.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IDRA' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.7   Max: 4.6
Current: -23

-62.7
4.6
» IDRA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

IDRA Guru Trades in Q1 2014

Paul Tudor Jones 23,810 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

IDRA Guru Trades in Q2 2014

Paul Tudor Jones 12,055 sh (-49.37%)
» More
Q3 2014

IDRA Guru Trades in Q3 2014

Paul Tudor Jones Sold Out
» More
Q1 2015

IDRA Guru Trades in Q1 2015

Steven Cohen 137,087 sh (New)
Paul Tudor Jones 22,100 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with IDRA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.30
IDRA's P/B is ranked higher than
65% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. IDRA: 3.30 )
Ranked among companies with meaningful P/B only.
IDRA' s 10-Year P/B Range
Min: 0.83   Max: 548
Current: 3.3

0.83
548
P/S 3127.14
IDRA's P/S is ranked lower than
111% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. IDRA: 3127.14 )
Ranked among companies with meaningful P/S only.
IDRA' s 10-Year P/S Range
Min: 0   Max: 3326.4
Current: 3127.14

0
3326.4
Current Ratio 18.76
IDRA's Current Ratio is ranked higher than
89% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. IDRA: 18.76 )
Ranked among companies with meaningful Current Ratio only.
IDRA' s 10-Year Current Ratio Range
Min: 0.02   Max: 18.76
Current: 18.76

0.02
18.76
Quick Ratio 18.76
IDRA's Quick Ratio is ranked higher than
89% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. IDRA: 18.76 )
Ranked among companies with meaningful Quick Ratio only.
IDRA' s 10-Year Quick Ratio Range
Min: 0.02   Max: 18.76
Current: 18.76

0.02
18.76

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.00
IDRA's Price/Net Cash is ranked higher than
77% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. IDRA: 4.00 )
Ranked among companies with meaningful Price/Net Cash only.
IDRA' s 10-Year Price/Net Cash Range
Min: 2.02   Max: 141.33
Current: 4

2.02
141.33
Price/Net Current Asset Value 4.00
IDRA's Price/Net Current Asset Value is ranked higher than
77% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 15.30 vs. IDRA: 4.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IDRA' s 10-Year Price/Net Current Asset Value Range
Min: 1.95   Max: 56.96
Current: 4

1.95
56.96
Price/Tangible Book 3.80
IDRA's Price/Tangible Book is ranked higher than
64% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. IDRA: 3.80 )
Ranked among companies with meaningful Price/Tangible Book only.
IDRA' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 413.2
Current: 3.8

1.9
413.2
Earnings Yield (Greenblatt) -14.30
IDRA's Earnings Yield (Greenblatt) is ranked lower than
68% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. IDRA: -14.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
IDRA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -16.5   Max: 164993.3
Current: -14.3

-16.5
164993.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HXXA.Germany,
Idera Pharmaceuticals Inc was incorporated in Delaware on May 25, 1989. The Company is a clinical stage biotechnology company. The Company is engaged in the discovery, development and commercialization of novel therapeutics for oncology and rare diseases. The Company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates including nucleic acid therapeutics that target biologic pathways implicated in disease processes. The Company first platform focuses on inhibiting over-activation of Toll-like receptors (TLRs) and the second is its gene silencing oligonucleotides (GSOs) platform. The Company TLR antagonist drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. The Company also has created compounds that are agonists of TLR3, TLR7, TLR8 and TLR9. Its TLR agonist drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9. The Company's drug candidates include IMO-8400 an novel synthetic oligonucleotide antagonist of TLR7, TLR8, and TLR9. It is developing IMO-8400 for the treatment of certain genetically defined forms of B-cell lymphoma and for the treatment of rare diseases. It is also conducting a Phase 1 clinical trial of IMO-9200 in healthy subjects, as well as additional preclinical studies of IMO-9200 for a selected autoimmune disease. The Company relies upon third parties to produce material for nonclinical and clinical testing purposes. The Company's competitors include Dynavax, InDex Pharmaceuticals AB, Mologen AG, BioLineRx Ltd., Innate Immunotherapeutics Ltd., VentiRx Pharmaceuticals Inc., Telormedix S.A., Gilead Sciences Inc., GlaxoSmithKline plc, AstraZeneca plc and Hoffmann-La Roch. The testing, manufacturing, labeling, advertising, promotion, export, and marketing of its drug candidates are subject to regulation by governmental authorities in Europe, the United States, and elsewhere throughout the world.
» More Articles for IDRA

Headlines

Articles On GuruFocus.com
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
Idera Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides Pipeline Update Aug 04 2009 

More From Other Websites
Idera to Present at Two June Investor Healthcare Conferences May 27 2015
Idera to Present at Two June Investor Healthcare Conferences May 27 2015
IDERA PHARMACEUTICALS, INC. Financials May 19 2015
Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors May 18 2015
Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors May 18 2015
10-Q for Idera Pharmaceuticals, Inc. May 14 2015
Idera Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update May 11 2015
Idera reports 1Q loss May 11 2015
Idera reports 1Q loss May 11 2015
Idera Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update May 11 2015
IDERA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 11 2015
10-K for Idera Pharmaceuticals, Inc. May 06 2015
5 Big Biotechs Not Keeping Up at All With Hot Biotech Sector in 2015 Apr 18 2015
Idera to Present at the 14th Annual Needham Healthcare Conference Apr 13 2015
Idera to Present at the 14th Annual Needham Healthcare Conference Apr 13 2015
Here are 10 local biotechs investing heavily in their future Apr 10 2015
Idera draws short-term call buyers Apr 06 2015
Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell... Apr 01 2015
Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell... Apr 01 2015
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Mar 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK